Caitong Securities said that overseas investment and financing are gradually picking up, pointing out that attention should be paid to companies that account for a relatively high share of overseas business and are developing rapidly in emerging businesses such as peptides. At the same time, positive suggestions were also given for clinical CROs with relatively abundant orders in hand.